HIMS 0.00%↑ one of the most polarizing names on the market. With 24.6% short interest, it’s either a landmine or a land grab.

Some dismiss it as another DTC fad. Others see the foundation of a next-gen healthcare platform. The truth is likely somewhere in between but the upside could be significant if the company keeps executing.

This isn’t about hype. It’s a sober breakdown of where Hims stands today—valuation, growth, margin trajectory, and what the market is pricing in (or missing entirely).

🔍 Company Snapshot

• Ticker / Name: HIMS 0.00%↑ / Hims & Hers Health, Inc.

• Market Cap: $6.29 B

• Sector / Industry: Healthcare / Telehealth & D2C healthcare

• Stock Type: High Grower

• Stock Price: $28.31

  

🔑 Key Thesis Points

1. Management Alignment

HIMS 0.00%↑ shows alignment with shareholders through 13.3% insider ownership, indicating commitment from management.

Their capital allocation strategy is smart, focusing on expanding into new healthcare verticals while maintaining profitability, which suggests effective use of resources for growth.

2. Growth Metrics

Hims & Hers Health has demonstrated impressive growth metrics, particularly in revenue. From 2020 to 2024, revenue increased from $148.88 million to $1,476.51 million, yielding a 4-year compound annual growth rate (CAGR) of approximately 77.4%. This growth reflects the company's ability to scale rapidly in the telehealth and D2C healthcare market.

For EPS, the transition from a loss of -$0.5 in 2020 to a profit of $0.5 in 2024 is notable. The company's ability to turn profitable, with net income of $126.0 million in 2024 compared to a loss of $23.5 million in 2023, underscores operational improvements.

3. Valuation

There’s been nonstop noise around HIMS 0.00%↑ valuation from wild optimism to full-on doom posts. And honestly, that confusion is part of why this opportunity still exists. So I pulled together a comparison of peers and quasi-peers to cut through the noise.

Comparative analysis has always been my go-to. It grounds the story in actual market context. When you stack HIMS 0.00%↑ next to names like GDRX 0.00%↑, LLY 0.00%↑, LFMD 0.00%↑, TDOC 0.00%↑, and PFE 0.00%↑ , the disconnect becomes obvious. This isn’t about narrative, it’s about numbers.

• HIMS 0.00%↑ is a standout — top-tier historical and projected growth, yet EV/Sales is modest.

• LLY 0.00%↑ is priced for perfection, no room for error.

• LFMD 0.00%↑ could be a dark horse — solid growth, rock-bottom valuation.

• TDOC 0.00%↑ and PFE 0.00%↑ nothing exciting going on here

• GDRX 0.00%↑ just isn’t moving the needle growth-wise.

The free cash flow (FCF) for 2024 was $209 million, with shares outstanding at approximately 222.18 million resulting in an FCF per share of $0.941. The FCF yield, 3.32%, is not bad, given the company's strong growth prospects and large TAM.

The valuation appears modest. Not screaming cheap, not frothy either. It reflects market expectations for future expansion and some real execution risk. But when you layer in the growth profile and margin structure, the risk/reward still looks asymmetric.

4. Risks

4.1. Regulatory Headwinds and Product Transition
After the FDA removed semaglutide from the shortage list in February 2025, Hims was forced to halt compounded GLP-1 sales — eliminating one of its most in-demand product lines.

The company swiftly pivoted to compounded liraglutide, which remains legally permissible. But the tradeoff is clear: liraglutide is less effective, requires daily injections, and has lower patient adherence. While the shift preserved some GLP-1 exposure, it’s a step down in efficacy and convenience. Long-term success in weight management will depend on whether HIMS 0.00%↑ can access branded GLP-1s through partnerships or discover alternative offerings that can scale with attractive unit economics.

4.2. Competitive Pressure from Scaled Players
HIMS 0.00%↑ operates in a space that’s drawing heavyweights. AMZN 0.00%↑ , in particular, is stepping up its telehealth push — and they come armed with unmatched infrastructure, a sticky ecosystem via Prime, and deep pricing flexibility.

The challenge for Hims? It doesn’t own IP, switching costs are low, and barriers to entry are eroding. If Amazon or other scaled players double down, it could drive up acquisition costs, compress margins, and chip away at market share. In this game, scale and capital increasingly dictate who survives.

4.3. Marketing Expenses

Marketing spend remains elevated at 46% of revenue. If subscriber growth or retention weakens, this cost structure could compress net margins and jeopardize HIMS 0.00%↑ ’ ability to scale toward its projected EBITDA targets.

5. Moat

Here we are — the famous “has no moat” section 😅

Sure, HIMS 0.00%↑ doesn’t own patented drugs or proprietary tech. But calling it moatless misses the full picture. The edge is softer but real.

• Execution-Driven Brand Trust
  HIMS 0.00%↑ has built emotional trust in highly stigmatized categories (ED, anxiety, hair loss). That takes time and nuance and while not a legal moat, it creates customer inertia. You don’t easily switch platforms for mental health meds or GLP-1s when one brand already “gets” you.

• High Retention + Personalization
  2.2M+ subscribers, 80% gross margins, and <5% churn isn’t just “good business” — it’s behavioral lock-in. Personalization and recurring prescriptions boost LTV and reduce the need to reacquire users.

• Content + Customer Acquisition Engine
  Their ability to blend DTC marketing, influencer campaigns, and SEO-optimized content is underrated. CACs are lower than peers because of this flywheel and replicating that brand/marketing blend isn’t easy.

• Operational Leverage at Scale
  With 80% gross margins and a lean fixed-cost base, every dollar of new revenue drops fast to the bottom line. This is a scaling moat — not a defensive one — but it matters.

• “Digital Shelf” Positioning
  Among Gen Z and Millennials, HIMS 0.00%↑ owns mental shelf space for digital-first healthcare. That’s a moat as long as the user base keeps aging into healthcare spend.

So... is it a Buffett-style moat? No.

Is it a strong enough edge to justify 4–6x forward sales in a market full of bloated, cash-burning DTC junk? Arguably yes.

6. Total Addressable Market (TAM)

To provide a comprehensive estimate, the TAM is broken down by key product categories, with a focus on U.S. market sizes, and considerations for global potential:

1. Mental Health:

   • Total U.S. mental health spending reached $225 billion in 2019 and is estimated to grow to $250 billion by 2024, assuming 2–3% annual growth.

     But Hims doesn’t compete across the full mental health market. It operates in a direct-to-consumer (D2C) telehealth segment — a subset with very different dynamics.

     • A RAND study found that from 2020 to 2022, telehealth drove a 53% increase in mental health-related spending.

     • Estimates suggest that 20–30% of U.S. mental health care is now delivered via telehealth.

     • Applying that range to the total $250B market gives a $50–75B TAM for U.S. telemental health.

     However, Hims plays specifically in the consumer-facing, self-pay D2C portion of that market — which is narrower.

     👉 Estimated U.S. TAM for Hims in telehealth mental health: $30 billion

2. Weight Loss:

   • The weight loss market grew to $93.8 billion in 2024. This includes prescription drugs, medical programs, commercial diet programs, and other services, driven by surging sales of GLP-1 weight loss medications like Wegovy and Zepbound. For HIMS 0.00%↑ , their weight loss offerings, particularly compounded peptides, are part of this market, making the full $93.8 billion U.S. TAM relevant.

3. Hair Loss:

   • The U.S. hair loss treatment market is approximately $10 billion, fully addressable by HIMS 0.00%↑ via telehealth and prescriptions.

4. Sexual Health:

   • The U.S. market for sexual health treatments, such as erectile dysfunction drugs, is estimated at $2.5 billion, which $HIMS can fully address through their telehealth platform.

5. Skincare:

   • The U.S. D2C skincare market is around $10 billion, with HIMS 0.00%↑ offering a subset, but for TAM, let's include the full market they can address, estimated at $10 billion.

Given $HIMS's current U.S. focus, the $150 billion TAM is U.S.-based, but global expansion could potentially double or triple this figure.

📊 Consensus Snapshot

🔹 Revenue Forecast (2025–2027)

• Revenue estimates show continued growth into 2027 with forecasts ranging from ~$3B to over $4B.

• Even the low end suggests sustained double-digit top-line expansion.

• Growth rates are expected to moderate over time:
  • 2025E: ~60%
  • 2026E: ~20%
  • 2027E: ~20%

• The sharp deceleration baked into 2026 could be overly conservative if GLP-1 momentum sustains.

The market is expecting growth to normalize, but with new product launches or better GLP-1 access, upside surprises are possible.

🔹 EPS Forecast (2025–2027)

• Profitability inflection is clear:
  • 2025E Avg EPS: $1.09
  • 2026E Avg EPS: $1.35
  • 2027E Avg EPS: $1.74

• High-end estimates even point to EPS > $2.00 by 2027, which would imply explosive margin leverage.

If execution remains tight and margin expansion continues, Hims could exceed Street expectations — especially if SG&A is kept lean.

🔹 Stock Price Target

• Current price: ~$28

• Street average target: $38.25 (+35%)

• High target: $68 (+140%)

• Low target: $22 (-22%)

• Analyst consensus: ✅ Buy

The skew is bullish — more analysts see asymmetric upside than downside. High-end price targets likely reflect confidence in long-term optionality (e.g., branded GLP-1 partnerships, expanding TAMs).

🔹 Company Guidance

Estimates align with the company's guidance and historical performance, suggesting they are achievable rather than overly optimistic, though EPS growth may face challenges from regulatory and competitive risks. Analyst coverage is moderate, with a consensus rating of "Buy" and an average price target of $38.25, reflecting a balanced but positive outlook.

🎯Realistic or Overly Optimistic?

🟢 Achievable IF:

• HIMS 0.00%↑ executes a branded GLP-1 access play or expands telehealth verticals faster than expected

• Churn stays low, and CACs remain stable

• SG&A leverage continues while maintaining growth

🔴 Overly optimistic IF:

• GLP-1 growth hits a wall due to regulation, or failed product transition

• Larger players (e.g., AMZN 0.00%↑ ) apply sustained pricing pressure

• EPS lift stalls due to reinvestment or retention challenges

🧠 What do I see that the market is missing ?

Most investors are fixated on the recent FDA action that forced HIMS 0.00%↑ to halt compounded semaglutide. That headline drove the stock down but it also distracted from what’s actually working.

Mental health and dermatology remain strong growth engines. These verticals are compounding with solid retention, and they aren’t dependent on GLP-1 momentum.

More importantly, the recent acquisition of a lab testing facility is a strategic move that unlocks vertical integration. It sets the foundation for personalized diagnostics, lower cost of care, and expanded margins — a play the market hasn’t fully priced in yet.

While the weight loss narrative just got more complex, the underlying business remains solid and the optionality is increasing, not shrinking.

🔹 Customer Feedback

HIMS 0.00%↑ has a TrustScore of 3 out of 5 on Trustpilot, based on over 6,000 reviews, indicating a moderate level of customer satisfaction. The distribution includes 5-star, 4-star, 3-star, 2-star, and 1-star ratings, my take while there are operational issues (e.g., cancellation policies, customer service), these are not insurmountable.

The positive reviews highlight strong product efficacy and customer satisfaction, which are critical for long-term success. The company's response rate to negative reviews (94%) within 2 weeks suggests they are addressing concerns, which could improve over time.

🎯 Target Price

💸 DCF-Based Valuation

My unlevered DCF model projects:

• Revenue CAGR (2023–2029): ~38%

• EBIT margin expands from -3% in 2023 to 9.5% by 2027

• Unlevered FCF reaches ~$465M by 2029

• WACC: 12.3%

• Exit multiple: 40x EV/FCF

• Terminal Value: $18.6B

• Cumulative PV of UFCF: $995M

• Equity Value: ~$10.6B

• Implied Share Price: $47.6

• Upside from current levels (~$28.3): +74.7%

🔍 Key Assumptions:

• Beta: 1.7 → Reflects risk premium for DTC healthcare + tech exposure

• No debt in capital structure → 100% equity-weighted

• Capex/Revenue: ~2–3%, steady throughout

• Tax rate normalization: 24% long-term

• FCF margin expands to 7.3% by 2029

The valuation supports a $40–$50 share price based on fundamentals, even without GLP-1 dominance. If branded access improves, or they compress CACs faster than expected, this model could prove conservative.

💸 PE Based Valuation

The current NTM P/E stands at 26.2×, but forward multiples can swing anywhere from 10× to 70× depending on:

• Execution and earnings surprise

• Macro sentiment and interest rates

• Competitive landscape (Amazon, GLP-1 disruption)

• Investor appetite for growth vs. profitability

In other words: multiple expansion is optionality, not a given.

• Base Case (25× P/E): Modest upside. 2026–2027 pricing reflects ~20–50% return from today’s ~$28/share, assuming steady execution but no market re-rating.

• Bull Case (30× P/E): Execution + sentiment improve. 50–85% upside over 2–3 years.

• Stretch Case (40× P/E): Market prices in dominance — branded GLP-1s, vertical integration, and stronger moat. Stock potentially more than doubles by 2027.

• Downside EPS misses or P/E compresses to 15–20×. That’s how you get back to ~$18–22.

🎯 $HIMS Target Price: $45

After building a full DCF model and running P/E scenario analysis, I’m assigning a $45 target price for Hims & Hers Health.

• 💸 DCF-based valuation: Implies fair value in the $47–50 range, assuming margin expansion and steady FCF growth.

• 📈 P/E-based valuation: At 30× 2027 EPS of $1.74, the implied share price is $52.2. Even at 25×, you’re still near $43.5.

• ⚖️ Current price: ~$28 → This suggests ~60% upside with a margin of safety if execution holds.

This target assumes continued scaling in core verticals (mental health, dermatology), steady GLP-1 contributions, and no major dilution or competitive disruption.

🧠 My Edge on $HIMS

The market is laser-focused on the FDA’s move against compounded GLP-1s — but that’s a short-term headwind, not a broken thesis. My edge is seeing what still works.

• Core growth engines like mental health, dermatology, and sexual health are scaling fast.

• The lab testing acquisition quietly opens the door to personalized, vertically integrated care with margin expansion and new revenue streams.

• And while Trustpilot reviews are mixed, the product satisfaction and brand loyalty are clear — these are fixable operational issues, not existential threats.

👉 With EPS compounding, new verticals coming online, and a DCF-supported target of $45, I believe the market is underpricing HIMS 0.00%↑ long-term potential.

📬 Subscribe to